Cancer Care Center recruiting for national prostate cancer study
Prostate cancer is the most commonly diagnosed cancer among American men. It is estimated that 16 percent of Caucasian men and 18 percent of African-American men will develop prostate cancer during their lifetime. Results from two randomized controlled clinical trials have suggested that that selenium and vitamin E may help to lessen the risk of developing prostate cancer.
Oncologists at Sharon Regional's Cancer Care Center, 2320 Highland Rd., Hermitage, are recruiting men over the age of 55 to participate in an important nationwide clinical trial, designed to determine whether dietary supplementation with selenium or vitamin E may, in fact, result in a lower risk of developing prostate cancer.
This clinical trial, the SELECT trial, is being conducted by the Southwest Oncology Group, and is available to men locally through the Allegheny Cancer Center and Sharon Regional. Men are considered eligible for participation if they have had a normal prostate examination and normal PSA within the past year. The volunteers will receive selenium, vitamin E, or placebos, and will be monitored for a period of seven to 12 years.
If you are interested in learning more about this or any of the other clinical trials currently underway at the Cancer Care Center, please call George Garrow, MD, director of medical oncology, or Darlene Washington, RN, at 724-983-5900.